Boston Scientific (BSX) slips Friday after acknowledging in a regulatory filing late Thursday receipt of a subpoena from the U.S. Health and Human Services department related to the drugmaker’s Cognis and Teligen line of defibrillator devices.
The subpoena, received May 5, requested information related to the 2008 launch of two brands of implanted cardiac defibrillators, or ICDs, made by Boston Scientific, the company said. The subpoena also sought information related to the performance of the devices between 2007 and 2009, and the operation of a “Physician Guided Learning Program,” the filing said.
Boston Scientific said it is cooperating with the request.
The company had total net sales of $7.14 billion last year for defibrillators and other implanted heart devices including pacemakers and stents, which prop open narrowed or weakened arteries.
Latest posts by Richard Carlisle (see all)
- Our Genes May Be To Blame For Our Love Of Unhealthy Food - Apr 24, 2017
- The Weed And The American Family Poll Offered Interesting Results - Apr 18, 2017
- PC Shipments Reported Their First Growth In 5 Years - Apr 13, 2017